Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Covington
Queensland Health
McKinsey
Cantor Fitzgerald
Boehringer Ingelheim
Cerilliant
Fuji
Mallinckrodt

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,367,701

« Back to Dashboard

Which drugs does patent 8,367,701 protect, and when does it expire?

Patent 8,367,701 protects XIIDRA and is included in one NDA.

This patent has thirty-two patent family members in eight countries.
Summary for Patent: 8,367,701
Title:Crystalline pharmaceutical and methods of preparation and use thereof
Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##
Inventor(s): Burnier; John (Pacifica, CA), Gadek; Thomas (Oakland, CA), Naud; Frederic (Binningen, CH)
Assignee: SARcode Bioscience Inc. (Brisbane, CA)
Application Number:13/289,172
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation; Delivery;

Drugs Protected by US Patent 8,367,701

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,367,701

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,447,077 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Sign Up
8,080,562 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Sign Up
8,871,935 Crystalline pharmaceutical and methods of preparation and use thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Accenture
Healthtrust
Johnson and Johnson
Daiichi Sankyo
Deloitte
US Army
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.